Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b oral TAK-279 in moderately to severely active Crohn's disease
NL-OMON59042Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zasocitinib in Crohn's disease, sponsored by Takeda. Primary endpoint: Endoscopic response at Week 12. Started Oct 2024; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON59042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59042.